FDA Approves First Generic Estradiol and Levonorgestrel Transdermal Patch
The US Food and Drug Administration has approved the first generic version of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), manufactured by Zydus Pharmaceuticals (USA) Inc. The patch is applied once weekly and is indicated for women with an intact uterus to manage moderate to severe vasomotor symptoms of menopause and to help prevent postmenopausal osteoporosis.
Unlike estrogen-only formulations, this transdermal system combines both an estrogen and a progestogen. The addition of the progestogen component is designed to lower the risk of endometrial hyperplasia that can occur with estrogen monotherapy in women who retain a uterus. Common adverse reactions occurring in 5% or more of patients include application site reactions, vaginal bleeding, breast pain, headache, depression, back pain, general pain, upper respiratory tract infections, and flu-like symptoms.
The medication is contraindicated in patients with undiagnosed abnormal genital bleeding, known or suspected breast cancer or estrogen-dependent neoplasia, active or previous deep vein thrombosis, pulmonary embolism, arterial thromboembolic disease, hepatic impairment, known thrombophilic disorders, or hypersensitivity to the active ingredients.
Key points
- The US FDA approved the first generic estradiol and levonorgestrel transdermal system (0.045 mg/0.015 mg per day), therapeutic equivalent to Climara Pro.
- The once-weekly patch is indicated for women with an intact uterus for moderate to severe menopausal vasomotor symptoms and postmenopausal osteoporosis prevention.
- The progestogen component is included to mitigate the risk of endometrial hyperplasia associated with unopposed estrogen therapy.
- The product is contraindicated in patients with a history of thromboembolic disease, breast cancer, liver dysfunction, thrombophilic disorders, or unexplained vaginal bleeding.
What it means for you
This approval provides a once-weekly transdermal alternative to daily oral hormone replacement therapy for women with an intact uterus. Healthcare providers in Pakistan should review patient contraindications carefully when considering combined hormone therapy and check with the Drug Regulatory Authority of Pakistan (DRAP) regarding local product availability and regulatory guidance.
FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.